Boehm G, Senger H, Spencker F B, Handrick W, Teichmann B, Krumbiegel P
Department of Pediatrics, University of Leipzig, Germany.
Pediatr Infect Dis J. 1991 Oct;10(10):739-42. doi: 10.1097/00006454-199110000-00004.
In 21 low birth weight infants with two regimens of antibiotic therapy during the first 3 days of life possible hepatotoxic side effects were studied 8 days after the last administration of the tested drugs. Fourteen of the infants were treated with ampicillin/gentamicin and 7 received cefotaxime/gentamicin. The serum concentrations of total bile acids, the activities of transaminases in serum and the cumulative 15N excretion in urine after administration of 3 mg of 15N-labeled methacetin/kg of body weight were used as markers of hepatotoxic side effects. Neither the concentrations of total bile acids (22.6 +/- 12.1 and 19.4 +/- 10.8 mM, respectively) nor the activities of transaminases (alanine aminotransferase, 0.27 +/- 0.06 vs. 0.30 +/- 0.09 mumol/second/liter; aspartate aminotransferase, 0.46 +/- 0.11 vs. 0.49 +/- 0.10 mumol/second/liter) were different between the two groups. In contrast the cumulative 15N excretion in urine was significantly lower in the group treated with cefotaxime/gentamicin than in the group treated with ampicillin/gentamicin (17.2 +/- 6.4 vs. 33.0 +/- 5.1% of intake; P less than 0.01) and also lower than the reported age-related reference values. On the 28th day of life no differences could be found between the cumulative 15N excretion in the urine of the infants treated with cefotaxime/gentamicin and the reported age-related reference values of this test. The results indicate a limited capacity of the monooxygenase system of the liver of low birth weight infants during the first weeks of life and a specific reversible influence of cefotaxime on this hepatocellular system. Further investigations are required to evaluate the clinical relevance of this drug-specific inhibition of the hepatic monooxygenase pathway.
对21例低出生体重儿在出生后前3天接受两种抗生素治疗方案,在最后一次给予受试药物8天后研究可能的肝毒性副作用。14例婴儿接受氨苄西林/庆大霉素治疗,7例接受头孢噻肟/庆大霉素治疗。血清总胆汁酸浓度、血清转氨酶活性以及给予3mg 15N标记的甲醋氨酚/千克体重后尿中15N的累积排泄量被用作肝毒性副作用的标志物。两组之间血清总胆汁酸浓度(分别为22.6±12.1和19.4±10.8mM)和转氨酶活性(丙氨酸转氨酶,0.27±0.06对0.30±0.09μmol/秒/升;天冬氨酸转氨酶,0.46±0.11对0.49±0.10μmol/秒/升)均无差异。相比之下,头孢噻肟/庆大霉素治疗组尿中15N的累积排泄量显著低于氨苄西林/庆大霉素治疗组(摄入量的17.2±6.4%对33.0±5.1%;P<0.01),也低于报道的年龄相关参考值。在出生第28天,头孢噻肟/庆大霉素治疗的婴儿尿中15N的累积排泄量与该试验报道的年龄相关参考值之间未发现差异。结果表明低出生体重儿出生后第一周肝脏单加氧酶系统功能有限,且头孢噻肟对该肝细胞系统有特定的可逆影响。需要进一步研究以评估这种药物特异性抑制肝单加氧酶途径的临床相关性。